event-trade登录编辑
🇺🇸 SECMindWalk Holdings Corp.Doubao · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:58:00·⟳ 抓取 04:58:56 +56s·⚡ 决策 09-15 05:01:45 +2m49s·42.8 天前

MindWalk(HYFT)FY2027一季度营收增21%、毛利率升至59%,但净亏损扩大49%至610万加元并获3000万美元无抵押信贷承诺

基本面喜忧参半且亏损端更重:营收仅383万加元,持续经营亏损同比扩大49%、调整后EBITDA亏损扩大38%,季度经营现金消耗400万加元而账上现金仅762万,7%利率的3000万美元债务工具只是具约束力条款书(目标60天签约)、主要用于弥补烧钱而非增量利好;盘后股价反跌约2.9%、买卖价差极大(买1.27/卖1.39)、成交极薄,缺乏可交易的正期望。

📄 原文MindWalk Holdings Corp.↗ 原文
----- earnings_release_sep_14_.htm ----- 6-K 1 earnings_release_sep_14_.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHAN…
不做 MindWalk Holdings Corp.(HYFT.US)
混合财报:营收/毛利率改善被亏损扩大49%、高现金消耗和短现金跑道抵消,3000万美元信贷仅具约束力条款书且本质为补流动性;盘后已下跌约2.9%,买卖价差约9%、成交极薄,无明确方向edge且执行滑点高,不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

HYFT盘后公布FY27Q1:营收+21%、毛利率升至59%是亮点,但净亏损扩大49%至610万加元、季度烧钱400万、现金降至762万,3000万美元7%无抵押信贷仅为条款书。市场盘后以下跌约2.9%回应,方向混合、流动性极差,不构成可交易edge。

🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 medium ↗ ↗

消息传播链

  1. 2026-09-14 16:58 ET首发SEC EDGAR 6-K Exhibit 99.1原文 ↗
    公司盘后提交6-K并同步发布FY27Q1财报新闻稿及3000万美元信贷承诺,17:00召开电话会
    市场反应:盘后股价约1.292美元,较收盘1.33美元跌约2.9%,盘后量约2.2万股
  2. 2026-09-14财经媒体转载Stock Titan非一手原文 ↗
    媒体概括为营收和毛利率增长但亏损扩大,尚无分析师上调/下调等二次解读,扩散程度低

关键理由

  • 营收连续增长且毛利率扩张10个百分点至58.6%,ReefIQ商业化与80%漏斗转为合伙结构提供长期经常性收入期权
  • 3000万美元无稀释、无抵押、无维护性契约的信贷承诺显著缓解账面现金仅762万加元、季度烧钱400万的短期流动性担忧

主要风险

  • 持续经营净亏损同比扩大49%、调整后EBITDA亏损扩大38%,且现金跑道短,信贷在最终协议签署前仍有不能提款/不能如期关闭的风险
  • 盘后下跌约2.9%、买卖价差近9%、成交极薄,微盘股执行滑点和波动风险高

反向证据

  • 做多前查反向 · 来源 filing · 日期 2026-09-14 · 影响 weakens
    持续经营净亏损扩大49%、调整后EBITDA亏损扩大38%、经营现金流出400万、现金仅剩762万加元,7%利率举债而非股权融资本身反映现金需求
    检索:HYFT MindWalk Q1 2027 loss widening cash burn credit facility dilution risk 原文 ↗

先例如何影响了这次决策

对本次决策的影响:缺乏先例叠加盘后负向价格信号与极差流动性,支持AVOID而非追多或博反弹

方向:无可信对齐先例;微盘亏损生物AI公司混合财报+债务融资的短期方向高度个案化

涨幅量级:不足以校准幅度

形态:本次盘后真实反应已为小幅下跌(-2.9%),与利好标题背离,提示市场更重亏损/烧钱

工具执行结果 · 成功 2 · 降级 1 · 失败 0 · 取消 0
  1. search_processed_events 成功 stock_tools HTTP · 23 ms
    {"result": "search_processed_events:agent query=`immunoprecise antibodies hyft sanabil $30 million credit facility | mindwalk holdings hyft fiscal q1 2027 earnings reefiq | mindwalk reefiq commercial launch revenue 21% gross marg`;结构化索引覆盖完整 72 小时;旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整),返回 0 条候选。未命中只表示这些 agen
  2. stock_quote 降级 stock_tools HTTP · 250 ms
    {
  3. web_search 成功 doubao_search · 2,210 ms
    豆包搜索结果(原始查询:MindWalk Holdings HYFT fiscal Q1 2027 earnings results revenue;API SearchType:web)

原文全文

展开原文 · 16,914 字
----- earnings_release_sep_14_.htm -----
6-K
1
earnings_release_sep_14_.htm
6-K
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of
September, 2026
.
Commission File Number:
001-39530
ImmunoPrecise Antibodies Ltd.
Industrious 823 Congress Ave Suite 300 Austin, Texas 78701, United States
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
☒
Form 40-F
☐
EXHIBIT INDEX
Exhibit
Description
99.1
Earnings Release dated September 14, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
IMMUNOPRECISE ANTIBODIES LTD.
Date: September 14, 2026
By:
/s/ Jennifer Bath
Name:
Jennifer Bath
Title:
Chief Executive Officer

----- hyft-ex99_1.htm -----
EX-99.1
2
hyft-ex99_1.htm
EX-99.1
EX-99.1
99.1
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
ReefIQ™ launched commercially, and a US$30 million unsecured credit facility commitment, drawn only as needed, adds balance-sheet flexibility with no dilution.
AUSTIN, Texas (September 14, 2026) - MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today reported financial results for its fiscal 2027 first quarter ended July 31, 2026. The quarter marked the commercial launch of ReefIQ™, MindWalk's data platform, and the start of its shift toward recurring, platform-based revenue.
•
Revenue increased 21.3% year over year to $3.8 million.
•
Gross profit increased 47.1% to $2.2 million; gross margin expanded to 58.6% from 48.3%.
•
Net cash used in operating activities declined to $4.0 million from $4.2 million, even as MindWalk stepped up sales and marketing investment behind the ReefIQ™ launch and enterprise rollout.
•
Net loss from continuing operations was $6.1 million, or $0.13 per share, compared with $4.1 million, or $0.09 per share, reflecting planned investment in the commercial infrastructure for ReefIQ™ enterprise adoption.
Business Highlights
•
Commercially launched ReefIQ™, MindWalk's data platform, in June, and is in active negotiations with multiple large pharmaceutical companies on enterprise deployments.
•
Roughly 80% of the commercial funnel by value now sits in partnership-structured engagements
rather than discrete projects, spanning data management, ReefIQ, and multi-target discovery.
•
Validated a production deployment on AMD Instinct GPUs with engineering partner AMD and Vultr, giving ReefIQ™ the compute capacity to onboard enterprise clients and run more programs at lower cost as recurring revenue scales.
•
Subsequent to quarter-end, obtained a binding commitment for a senior unsecured revolving credit facility of up to US$30 million at a fixed 7.00% rate, with no financial maintenance covenants, no warrants or conversion feature, and no pledge of assets, providing the balance sheet to scale ReefIQ™ enterprise onboarding without dilution.
"We delivered a strong quarter, with revenue up 21% and gross margin expanding to 59%, while launching ReefIQ™ into a market moving toward exactly what we built," said Jennifer Bath, PhD, President and Chief Executive Officer of MindWalk. "Our discovery business, which pairs wet-lab biologics with
in silico
capabilities for 19 of the top 20 pharmaceutical companies, is the foundation. On top of it, ReefIQ opens the door to enterprise partnerships of a scale well beyond our historical recurring agreements, and new partner engagements under discussion are increasingly structured as platform partnerships, where we share in the economics of the assets we help create. The larger loss this quarter reflects deliberate investment in ReefIQ's enterprise rollout."
"The US$30 million facility we announced today gives us the flexibility to fund that rollout as needed, without issuing a single share," continued Dr. Bath. "No warrants or conversion feature, and no pledge of our assets. Our commercial model is shifting to recurring, compounding revenue with ReefIQ at its center, and this gives us the balance sheet to make that shift on our own terms."
Fiscal First Quarter 2027 Financial Summary
Quarter ended July 31 (in thousands of Canadian dollars, except per-share data)
Metric
FQ1 2027
FQ1 2026
Change
Revenue
3,834
3,161
+21%
Gross profit
2,246
1,527
+47%
Gross margin
58.6%
48.3%
+10.3 pts
Total operating expenses
8,375
5,686
+47%
Operating loss
(6,129)
(4,159)
+47%
Net loss from continuing operations
(6,085)
(4,088)
+49%
Net loss for the quarter (1)
(6,085)
(2,959)
+106%
Loss per share, continuing operations
(0.13)
(0.09)
(0.04)
Net cash used in operating activities
(4.0M)
(4.2M)
-4%
Adjusted EBITDA from continuing operations
(5,091)
(3,702)
-38%
(1) The prior-year period includes $1.1 million of net income from discontinued operations. There were no discontinued operations in the current period.
Non-IFRS Measures.
This release includes Adjusted EBITDA, a non-IFRS financial measure defined as net loss before income taxes, amortization and depreciation, interest, foreign exchange gains and losses, and share-based payments. Management uses Adjusted EBITDA to evaluate operating performance. It has no standardized meaning under IFRS and may not be comparable to similar measures presented by other companies. A reconciliation of net loss to Adjusted EBITDA is provided at the end of this release.
Fiscal First Quarter Financial Results
Revenue for the three months ended July 31, 2026, was $3.8 million, up 21.3% from $3.2 million in the prior-year period. Gross profit rose 47.1% to $2.2 million, and gross margin expanded to 58.6% from 48.3%, as revenue grew on a cost of sales that held at $1.6 million.
Operating expenses were $8.4 million, compared with $5.7 million. Sales and marketing expenses rose to $3.2 million from $1.3 million, reflecting planned investment in the commercial team and infrastructure to bring ReefIQ™ to market and to onboard and scale enterprise deployments as agreements are signed, including non-recurring costs incurred in the quarter. General and administrative expenses were $3.9 million, compared with $3.3 million, with the increase primarily non-cash stock-based compensation. Research and development expenses were $1.3 million, compared with $1.0 million, reflecting additional engineering capacity to support the commercial development of the platform.
Operating loss was $6.1 million, compared with $4.2 million, as planned investment in the ReefIQ enterprise rollout and higher non-cash stock-based compensation more than offset a $0.7 million increase in gross profit. Net loss from continuing operations was $6.1 million, or $0.13 per share, compared with $4.1 million, or $0.09 per share. Total net loss was $6.1 million, compared with $3.0 million in the prior-year period, which included $1.1 million of income from discontinued operations.
Net cash used in operating activities was $4.0 million, compared with $4.2 million in the prior-year period, despite the increase in operating expenses, reflecting the non-cash nature of much of the G&A increase. Cash was $7.6 million at July 31, 2026, compared with $11.3 million at April 30, 2026, before the US$30 million facility commitment described below.
Subsequent Event
On September 14, 2026, MindWalk announced a binding commitment from Sanabil (Cayman) for a senior unsecured revolving credit facility of up to US$30 million at a fixed 7.00% interest rate, drawn as needed. The facility carries no financial maintenance covenants, no warrants or conversion feature, and no pledge of MindWalk assets. Proceeds are intended to support MindWalk's shift to recurring, platform-based revenue: onboarding ReefIQ™ and LensAI™ enterprise clients as agreements are signed, and participating in the platform partnerships that increasingly define its commercial model, along with its biologics programs, working capital, and general corporate purposes. The term sheet is binding on both parties, and MindWalk and Sanabil (Cayman) will negotiate a definitive credit agreement with a target closing within 60 days.
Conference Call and
Webcast Details
Event Date and Time:
Monday, September 14, 2026, at 5:00 p.m. Eastern Time
The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s Investor Relations pages at:
https://ir.mindwalkai.com/events-and-presentations/default.aspx
Analyst registration URL:
https://events.q4inc.com/analyst/231176031?pwd=m63SIFiS
Webcast Attendee URL:
https://events.q4inc.com/attendee/231176031
Anyone listening to the call is encouraged to read the Company’s periodic reports available on the Company’s profile at
www.sedarplus.ca
and
www.sec.gov
, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About MindWalk Holdings Corp.
MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require, integrating AI, data, and advanced wet lab capabilities into one connected discovery ecosystem. At its core is HYFT® Technology, a proprietary, function-aware representation of biology. Its HYFT pattern-objects span sequence and structural biology and, refined over 20 years of curation, form a continuously evolving biological representation of 660 million patterns and 25 billion relationships. This enriched biological representation is the architecture behind ReefIQ™, the biological data substrate that provides context for life sciences, enriching data at ingestion and growing more valuable with each program run on it, and LensAI™, the reasoning and application layer for target discovery, candidate diligence, portfolio decision support, and the agentic AI workflows pharmaceutical companies are now deploying. By design, value compounds in this HYFT representation layer, not in any individual AI model that runs on top of it.
Investor Contact
Louie Toma, CPA, CFA, Managing Director, CoreIR, investors@mindwalkai.com
Trademarks
HYFT® is a registered trademark of MindWalk Holdings Corp. ReefIQ™ and LensAI™ are trademarks of MindWalk Holdings Corp. or its subsidiaries; ReefIQ™ registration is pending. All other trademarks are the property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including: risks relating to MindWalk’s history of net losses and its ability to achieve or sustain profitability; the level and trend of operating cash usage and MindWalk’s ability to fund operations; the risk that MindWalk and the lender do not negotiate and execute a definitive credit agreement, or do not do so by the target closing date, and MindWalk’s ability to satisfy the conditions to closing and to drawing under the facility; the market acceptance and commercial outcomes of ReefIQ™ and LensAI™, including the ability to convert engagements into contracted, recurring arrangements; the build-out and certification of compliance capabilities for regulated workloads; the technical performance of AI-based discovery methods and of the underlying compute infrastructure; the outcomes and financial effects of the divestiture of non-core operations; intellectual property risks, including the status and scope of pending patent applications; the ability to enter into pharmaceutical, infrastructure, or other partnership arrangements; competition; regulatory determinations; and capital markets conditions. Additional information is available in MindWalk’s Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, MindWalk undertakes no obligation to update any forward-looking statement. [Legal to review tailored risk factors before issuance.]
Source: MindWalk Holdings Corp.
The reconciliation of Net Loss of continuing operations to Adjusted EBITDA is presented in the table below:
Three months ended
July 31,
(in thousands)
2026
$
2025
$
Net loss
(6,085
)
(4,088
)
Income taxes
158
(91
)
Amortization and depreciation
266
201
Foreign exchange realized loss
(23
)
136
Interest expense
55
59
Interest, accretion and other income
(18
)
(5
)
Unrealized foreign exchange loss
(184
)
31
Share-based payments
740
55
Adjusted EBITDA
(5,091
)
(3,702
)
*All financial figures are in Canadian Dollars (CAD) unless otherwise stated.
MINDWALK HOLDINGS CORP.
CONDENSED INTERM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Unaudited - Expressed in Canadian dollars)
Three months ended July 31,
(in thousands, except share data)
2026
$
2025
$
REVENUE
3,834
3,161
COST OF SALES
1,588
1,634
GROSS PROFIT
2,246
1,527
EXPENSES
Research and development
1,285
1,049
Sales and marketing
3,196
1,343
General and administrative
3,894
3,294
8,375
5,686
Loss before other income (expenses) and income taxes
(6,129
)
(4,159
)
OTHER INCOME (EXPENSES)
Grant income
—
6
Interest, accretion and other income
18
5
Unrealized foreign exchange loss
184
(31
)
202
(20
)
Loss before income taxes and discontinued operations
(5,927
)
(4,179
)
Income taxes
(158
)
91
NET LOSS FROM CONTINUING OPERATIONS
(6,085
)
(4,088
)
NET INCOME FROM DISCONTINUED OPERATIONS
—
1,129
NET LOSS FOR THE PERIOD
(6,085
)
(2,959
)
OTHER COMPREHENSIVE INCOME (LOSS)
Items that will be reclassified subsequently to loss
Exchange difference on translating foreign operations
(18
)
70
COMPREHENSIVE LOSS FOR THE PERIOD
(6,103
)
(2,889
)
LOSS PER SHARE FROM CONTINUING OPERATIONS– BASIC AND DILUTED
(0.13
)
(0.09
)
INCOME PER SHARE FROM DISCONTINUED OPERATIONS– BASIC AND DILUTED
—
0.02
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
46,807,089
46,154,118
MINDWALK HOLDINGS CORP.
CONDENSED INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Unaudited - Expressed in Canadian dollars)
(in thousands)
July 31,
2026
$
April 30,
2026
$
ASSETS
Current assets
Cash
7,623
11,348
Amounts receivable, net
2,020
2,529
Taxes receivable
347
472
Inventory
611
492
Unbilled revenue
851
581
Prepaid expenses
762
798
12,214
16,220
Restricted cash
128
126
Deposit on equipment
26
25
Property and equipment
3,997
4,047
Deferred tax asset
958
958
Total assets
17,323
21,376
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities
5,442
4,178
Deferred revenue
529
1,073
Income taxes payable
188
81
Leases
483
457
6,642
5,789
Leases
3,001
3,069
Deferred income tax liability
769
769
Total liabilities
10,412
9,627
SHAREHOLDERS' EQUITY
Share capital
137,788
137,263
Contributed surplus
14,848
14,108
Accumulated other comprehensive income
3,103
3,121
Accumulated deficit
(148,828
)
(142,743
)
6,911
11,749
Total liabilities and shareholders’ equity
17,323
21,376
MINDWALK HOLDINGS CORP.
CONDENSED INTERM CONSOLIDATED STATEMENTS OF CASH FLOWS
For the three months ended July 31, 2026 and 2025
(Unaudited - Expressed in Canadian Dollars)
Three months ended July 31,
(in thousands)
2026
$
2025
$
Operating activities:
(Note 2)
Net loss for the period
(6,085
)
(2,959
)
Items not affecting cash:
Amortization and depreciation
266
942
Foreign exchange
(142
)
41
Share-based expense
740
55
(5,221
)
(1,921
)
Changes in non-cash working capital related to operations:
Amounts receivable
581
(850
)
Inventory
(119
)
(84
)
Unbilled revenue
(237
)
(627
)
Prepaid expenses
39
(329
)
Accounts payable and accrued liabilities
1,216
(986
)
Sales and income taxes payable and receivable
214
279
Deferred revenue
(515
)
305
Net cash used in operating activities
(4,042
)
(4,213
)
Investing activities:
Purchase of property and equipment
(78
)
(282
)
Deferred acquisition payments
—
(312
)
Net cash used in investing activities
(78
)
(594
)
Financing activities:
Proceeds on share issuance, net of transaction costs
525
(48
)
Repayment of leases
(179
)
(323
)
Net cash used in financing activities
346
(371
)
Increase (decrease) in cash during the period
(3,774
)
(5,178
)
Cash included in asset held for sale
—
(646
)
Foreign exchange
51
57
Cash – beginning of the period
11,474
10,791
Cash – end of the period
7,751
5,024
Cash is comprised of:
Cash
7,623
4,897
Restricted cash
128
127
7,751
5,024
Cash paid for interest
—
—
Cash paid for income tax
—
—
Cash from discontinued operations:
Net cash used in operating activities
—
754
Net cash used in investing activities
—
(100
)
Net cash used in financing activities
—
(359
)
Source: MindWalk Holdings Corp.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。